Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Undisclosed mRNA Program is a preclinical drug discovery initiative by Molecure S.A. (formerly OncoArendi Therapeutics) focused on identifying small molecule therapeutics that target messenger RNA (mRNA) for the treatment of cancer. This program leverages a proprietary platform to discover small molecules capable of binding to specific RNA secondary or tertiary structures, thereby modulating the stability or translation of oncogenic mRNA transcripts. By targeting mRNA directly, the program aims to inhibit the production of disease-driving proteins that are often considered "undruggable" by traditional protein-targeting small molecules. As of early 2024, the program is in the hit-to-lead stage of development for various oncology indications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Undisclosed mRNA Program (Molecure).